While anti-estrogen therapy combined with CDK 4/6 inhibition is the standard of care for HR+/HER2- breast cancer patients diagnosed with locally advanced or metastatic disease progression following endocrine therapy, this combination therapy only modestly prolongs patient survival (30). The gene discussed is ERBB2; the disease is breast carcinoma.